Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Temozolomide × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 75 Neoplasm Metastasis 9 Brain Neoplasms 9 Uveal Melanoma 7 Skin Neoplasms 5 Breast Neoplasms 4 Glioblastoma 2 Central Nervous System Neoplasms 2 Zollinger-Ellison Syndrome 1 Vipoma 1 Somatostatinoma 1 Sezary Syndrome 1 Recurrence 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non functioning pancreatic endocrine tumor 1 Neuroendocrine Tumors 1 Neoplasms, Second Primary 1 Neoplasms 1 Mycosis Fungoides 1 Multiple Endocrine Neoplasia Type 2b 1 Multiple Endocrine Neoplasia Type 2a 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma, Cutaneous Malignant 1 Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma 1

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Microarray Analysis 1 Ipilimumab 1 Genetic Testing 1 Gene Expression Profiling 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Biopsy 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743126 2026-04-13

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡